The Cancer Letter

Inside information on cancer research and drug development

NCI Trials

NCI Trials for May

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase 1 – 10187

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma

National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128

Phase II – EA9171

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572

Phase II – NRG-GU006

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer

NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183

Phase III – CCTG MA.39

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711

Phase Other – ANBL17B5-Q

Growth Factor Receptor Trafficking and Neuroblastoma Differentiation

Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
By Claire Marie Porter
Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
By Ze’ev Ronai
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account